Nanjing Vazyme Biotech Co., Ltd

SHSE:688105 Rapport sur les actions

Capitalisation boursière : CN¥9.2b

Nanjing Vazyme Biotech Croissance future

Future contrôle des critères 5/6

Nanjing Vazyme Biotech is forecast to grow earnings and revenue by 76.3% and 23.8% per annum respectively. EPS is expected to grow by 75.8% per annum. Return on equity is forecast to be 7.7% in 3 years.

Informations clés

76.3%

Taux de croissance des bénéfices

75.8%

Taux de croissance du BPA

Biotechs croissance des bénéfices44.8%
Taux de croissance des recettes23.8%
Rendement futur des capitaux propres7.7%
Couverture par les analystes

Low

Dernière mise à jour19 Sep 2024

Mises à jour récentes de la croissance future

Recent updates

Nanjing Vazyme Biotech Co., Ltd's (SHSE:688105) 45% Price Boost Is Out Of Tune With Revenues

Oct 08
Nanjing Vazyme Biotech Co., Ltd's (SHSE:688105) 45% Price Boost Is Out Of Tune With Revenues

Is Nanjing Vazyme BiotechLtd (SHSE:688105) Using Debt In A Risky Way?

Jun 26
Is Nanjing Vazyme BiotechLtd (SHSE:688105) Using Debt In A Risky Way?

Nanjing Vazyme Biotech Co.,Ltd's (SHSE:688105) Shares Climb 31% But Its Business Is Yet to Catch Up

Mar 06
Nanjing Vazyme Biotech Co.,Ltd's (SHSE:688105) Shares Climb 31% But Its Business Is Yet to Catch Up

Prévisions de croissance des bénéfices et des revenus

SHSE:688105 - Estimations futures des analystes et données financières antérieures (CNY Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20262,416365N/A4751
12/31/20251,970297N/A3971
12/31/20241,572104N/A4361
9/30/20241,40324772N/A
6/30/20241,36426-6734N/A
3/31/20241,285-1512181N/A
12/31/20231,286-71-80153N/A
9/30/20232,133-232152589N/A
6/30/20232,520-101126649N/A
3/31/20232,896112-128553N/A
12/31/20223,569594-228735N/A
9/30/20222,885878-367445N/A
6/30/20222,663900-291440N/A
3/31/20222,302773-123453N/A
12/31/20211,869678355617N/A
9/30/20211,715767315583N/A
12/31/20201,564822651804N/A
12/31/201926826-515N/A
12/31/20181711-36-4N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: 688105's forecast earnings growth (76.3% per year) is above the savings rate (2.9%).

Bénéfices vs marché: 688105's earnings (76.3% per year) are forecast to grow faster than the CN market (25.8% per year).

Croissance élevée des bénéfices: 688105's earnings are expected to grow significantly over the next 3 years.

Chiffre d'affaires vs marché: 688105's revenue (23.8% per year) is forecast to grow faster than the CN market (14% per year).

Croissance élevée des revenus: 688105's revenue (23.8% per year) is forecast to grow faster than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: 688105's Return on Equity is forecast to be low in 3 years time (7.7%).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y